| Trial ID # | NCT02734004; MEDIOLA |
| Phase | I/II |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Bevacizumab, Durvalumab, Olaparib |
| Eligible Participant | Advanced solid tumors with no prior PARP inhibitor or PD-1/PD-L1 inhibitor |
| Patients Enrolled | 288 [ovarian: 31 Pt-S non-gBRCA MUT; median 1 prior therapy (1-2)] |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | CBR, ORR, DCR, DoR, PFS, OS, evaluated per RECIST |
| Biomarkers | gBRCA1/2 |
| Efficacy | Bev+Ola+Dur, non-gBRCA MUT (n=31): |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Promising activity of bevacizumab+olaparib+durvalumab in non-gBRCA MUT patients regardless of LOH score and mutation status of common DDR genes |
| Reference | Drew Y et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Annals Oncol (2020) 31 (suppl_4): abstract 814MO MEDIOLA Examines Triplet Therapy in Ovarian Cancer — New cohort adds bevacizumab to olaparib /durvalumab combo, MedPage today 10/7/2020 Bannerjee S et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO (2022) abstract 529MO Drew Y et al. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res (2024) 30(1):50-62 |